Ameriprise Financial Inc Gossamer Bio, Inc. Transaction History

Ameriprise Financial Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.48 - $1.08 $18,797 - $42,293	39,161 New	39,161 $35,000
Q2 2021 Aug 16, 2021	SELL	$8.0 - $9.75 $244,816 - $298,369	-30,602 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$8.63 - $10.94 $9,406 - $11,924	-1,090 Reduced 3.44%	30,602 $283,000
Q4 2020 Feb 12, 2021	SELL	$8.3 - $13.59 $165,585 - $271,120	-19,950 Reduced 38.63%	31,692 $307,000
Q3 2020 Nov 16, 2020	BUY	$11.3 - $14.75 $279,505 - $364,841	24,735 Added 91.93%	51,642 $641,000
Q2 2020 Aug 14, 2020	BUY	$9.52 - $15.98 $60,728 - $101,936	6,379 Added 31.07%	26,907 $350,000
Q1 2020 May 15, 2020	SELL	$8.0 - $15.48 $4,000 - $7,740	-500 Reduced 2.38%	20,528 $208,000
Q4 2019 Feb 14, 2020	SELL	$14.82 - $26.79 $12,626 - $22,825	-852 Reduced 3.89%	21,028 $329,000
Q3 2019 Nov 14, 2019	SELL	$16.02 - $22.47 $687,258 - $963,963	-42,900 Reduced 66.22%	21,880 $368,000
Q2 2019 Aug 14, 2019	SELL	$16.12 - $22.89 $14,508 - $20,601	-900 Reduced 1.37%	64,780 $1.44 Million
Q1 2019 May 15, 2019	BUY	$17.58 - $23.97 $1.15 Million - $1.57 Million	65,680 New	65,680 $1.42 Million

109

167M

430K

519K

Ticker GOSS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,954,000
Market Cap $84.6M
Description
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony...

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Ameriprise Financial Inc with notifications on news.